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Abstract
Background: Antipsychotic-induced weight gain
constitutes a major unresolved clinical problem which
may ultimately be associated with reducing life
expectancy by 25 years. Overweight is associated with
brain deterioration, cognitive decline and poor quality
of life, factors which are already compromised in
normal weight patients with schizophrenia.
Here we outline the current strategies against
antipsychotic-induced weight gain, and we describe
peripheral and cerebral effects of the gut hormone
glucagon-like peptide-1 (GLP-1). Moreover, we
account for similarities in brain changes between
schizophrenia and overweight patients.
Discussion: Current interventions against
antipsychotic-induced weight gain do not facilitate a
substantial and lasting weight loss. GLP-1 analogs
used in the treatment of type 2 diabetes are
associated with significant and sustained weight loss
in overweight patients. Potential effects of treating
schizophrenia patients with antipsychotic-induced
weight gain with GLP-1 analogs are discussed.
Conclusions: We propose that adjunctive treatment
with GLP-1 analogs may constitute a new avenue to
treat and prevent metabolic and cerebral deficiencies
in schizophrenia patients with antipsychotic-induced
weight gain. Clinical research to support this idea is
highly warranted.
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Background
Schizophrenia is a severe and heterogeneous brain disease
with a prevalence of approximately 0.5% in the world
population [1]. Antipsychotics constitute the cornerstone
in the treatment of schizophrenia. At the same time, much
of the excess mortality in patients with schizophrenia may
be attributed to metabolic side effects induced by antipsy-
chotics [2]. The prevalence of overweight (body mass
index (BMI) ≥25 kg/m2) and obesity (BMI ≥30 kg/m2) has
been estimated at approximately 60% among schizophre-
nia patients [3] compared to less than 20 to 30% in the
general population [4-7]. Accordingly, patients with schi-
zophrenia may lose 25 or more years of life expectancy,
with the majority of this excess in premature deaths being
attributed to obesity-related cardiovascular disease and
not to suicide [2,8].
Both genetic and environmental factors are contributing
to this pronounced co-morbidity between schizophrenia
and overweight [9,10]. Among the latter, antipsychotic
drugs and, especially, second generation antipsychotics
(SGAs) play a pivotal role [11,12]. Particularly, clozapine
and olanzapine are associated with excessive weight gain
(up to 2 kg per month) [13,14], but also the metabolism of
glucose and lipids is affected to a varying degree [15,16].
Non-alcoholic fatty liver disease (NAFLD), which is a
commonly known complication to obesity, may also be a
possible side effect of antipsychotic drug treatment, and a
high prevalence of NAFLD has been observed in schizo-
phrenia patients [16]. Thus, in the present-day clinical
setting optimal antipsychotic treatment is often compro-
mised due to antipsychotic-induced weight gain and
‘dysmetabolism’.
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Obesity is considered the single most important risk fac-
tor for development of dyslipidaemia, diabetes, cardiovas-
cular disease and ultimately premature death [17]. Also,
obesity is associated with stigmatization and compromised
quality of life [18,19]. According to the World Health
Organization, schizophrenia is one of the seven most dis-
abling diseases as measured in ‘years lived with disability’
among 15 to 44 year-olds, while diabetes is number 20
[20]. Co-morbidity between schizophrenia and obesity is
likely to further impair quality of life and shorten the life
span. Moreover, medical costs for obese individuals (with-
out psychiatric co-morbidity) are 30% higher than those of
normal weight individuals [21]. Accordingly, initiatives to
promote a healthier weight will also have health economic
benefits [22].
The following section begins by outlining current strate-
gies against antipsychotic-induced weight gain, and by
describing both peripheral and cerebral effects of the gut
hormone glucagon-like peptide-1 (GLP-1). Next, we
account for similarities in brain changes between schizo-
phrenia [23] and overweight patients [24]. Finally, we pro-
pose that adjunctive treatment with a GLP-1 analog holds
promise as a novel method to treat metabolic and cerebral
deficiencies in schizophrenia patients with antipsychotic-
induced weight gain.
Discussion
Current interventions against antipsychotic-induced
weight gain
Current interventions against antipsychotic-induced
weight gain fall into three categories. The first category
involves changing antipsychotic medication to a com-
pound less prone to result in weight gain. This strategy is
recommended in clinical guidelines and results in a mod-
est slowing of antipsychotic-induced weight gain to
approximately 1.9 kg [11]. Change of medication, however,
may increase the risk of exacerbating psychotic symptoms
[11]. The second category involves lifestyle intervention
and/or cognitive therapy and appears to slowdown the
SGA-induced weight gain by 2.6 kg after 3 to 4 months;
4.2 kg after 6 months; and 3.1 kg after 12 to 18 months of
treatment [25]. Finally, adjuvant medical treatment, the
third category, has been attempted with numerous drugs,
including ephedrine, sibutramine, orlistat, nizatidine,
cimetidine, naltrexone, amantadine, reboxetine, fluoxetine,
topiramate, dextroamphetamine, d-fenfluramine, famoti-
dine, fluvoxamine, phenylpropanolamine, rosiglitazone,
metformin and the combination of metformin and sibutra-
mine [26]. Metformin is by far the most investigated of
these drugs and is associated with the most pronounced
deceleration of antipsychotic-induced weight gain: 2.9 kg
over 13 weeks compared with placebo [26]. Metformin,
however, is considered a weight neutral intervention in the
treatment of type 2 diabetes [27].
Notably, all current interventions are weight neutral at
best. This is the case because a weight reducing interven-
tion may mask a net weight gain (for example, a reported
weight loss of 4 kg may be based on a 2 kg weight gain in
the intervention group compared with a 6 kg weight gain
in the placebo group [28]). Absolute, placebo-controlled
weight loss has only been achieved by means of resource-
demanding interventions comprising strict diets and
intensive physical training among hospitalized patients
[29] or during short treatment periods (≤12 weeks) [30].
In the general population, treatment of obesity often
comprises a combination of diet, exercise, modification of
daily routines and medication [31]. Currently, orlistat
(a lipase inhibitor), sibutramine (a serotonin-norepinephr-
ine reuptake inhibitor) and sympathomimetics are the
only approved drugs with the indication obesity [32]. Bar-
iatric surgery (for example, gastric bypass surgery) is the
single most efficient way to achieve lasting weight loss.
However, this intervention is not without risk and, there-
fore, only indicated in selected patients (for example, mor-
bid obesity (BMI ≥40 kg/m2)) [33].
Thus, there is an exigent need for better treatment stra-
tegies as well as a deeper understanding of the physiologi-
cal consequences of the weight gain and the metabolic
side effects associated with antipsychotic drugs. One such
strategy may involve the effects of currently available
GLP-1 analogs.
GLP-1 physiology and GLP-1 based treatment
GLP-1 is a gut peptide hormone synthesized in endocrine
L cells in the intestinal mucosa. GLP-1 is secreted into
circulation after food intake. In the pancreas, GLP-1
stimulates glucose-induced insulin secretion (an incretin
hormone) and inhibits glucagon secretion, thereby sub-
stantially contributing to maintaining the glucose homeos-
tasis [34]. Activation of both peripheral GLP-1 receptors
and GLP-1 receptors in the central nervous system
reduces appetite and food intake thereby ensuring that
body weight is kept down. In accordance with these obser-
vations, GLP-1 analogs for the treatment of type 2 diabetes
have been developed (generally lowering HbA1c approxi-
mately 1%). A recent meta-analysis of studies of obese
patients (with and without type 2 diabetes) demonstrated
that ≥20 weeks of treatment with a GLP-1 analog (com-
pared to other antidiabetic drugs, including metformin)
induced a weight loss of 3 kg [35]. Since previous antidia-
betic treatment strategies are generally associated with
weight gain, the weight reducing effect of GLP-1 analogs
may be of vital importance in the treatment of type
2 diabetes.
Clinically, the degree of weight loss appears to be posi-
tively correlated with the dose of GLP-1 analog. A recent
two-year prospective study (including non-diabetic
patients with baseline BMI ≥30 randomized to treatment
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with the GLP-1 analog liraglutide (2.4 to 3.0 mg once-
daily) or placebo) reported a weight loss of 7.8 kg (com-
pared to a 2 kg weight loss in the placebo group) [36].
Moreover, preclinical studies have indicated that GLP-1
analog treatment can reduce lipid accumulation in the
liver [37,38].
Interestingly, a preclinical study has shown that olanza-
pine-induced weight gain and metabolic derangements in
rats are reversed after treatment with the GLP-1 analog
liraglutide [39].
GLP-1 analogs
At present, six different GLP-1 analogs have been subject
to trials: exenatide (Eli Lilly), liraglutide (Novo Nordisk),
albiglutide (GlaxoSmithKline), taspoglutide (Ipsen and
Roche), lixisenatide (Sanofi-Aventis) and LY2189265 (Eli
Lilly). Only exenatide and liraglutide have been approved
by the U.S. Food and the Drug Administration and
European Medicines Agency. GLP-1 analogs have the
indication type 2 diabetes in combination with metfor-
min and/or sulphonylurea, when treatment with these
drugs is insufficient. Much academic and commercial
effort is being put into investigating the possibility of
extending the indication to obesity. Both exenatide and
liraglutide are administered subcutaneously. Exenatide
exists in two formulations: twice daily (Byetta®) and once
weekly (Bydureon®, Eli Lilly and Company, Indianapolis,
Indiana, USA). Liraglutide (Victoza®, Novo Nordisk A/S,
Bagsvaerd, Denmark) is administered once daily.
The major side effects of exenatide and liraglutide are
mild to moderate nausea and vomiting. These side
effects are dose-dependent and decline over time and
they do not explain the observed weight loss associated
with GLP-1 analog treatment [40]. The incidence of
treatment-associated hypoglycemia is low (European
Medicines Agency).
Cerebral effects of GLP-1
Besides the effects of GLP-1 analogs on hyperglycemia and
obesity (and possibly on hepatic lipid deposition), activation
of central GLP-1 receptors may stimulate neural plasticity
and prevent apoptosis, thereby suggesting involvement of
GLP-1 in neuroprotection and learning [41,42]. An animal
model of Alzheimer’s disease has been used to show that
the GLP-1 analog liraglutide prevents memory impairment
and increases both neurogenesis as well as synaptic plasti-
city in the hippocampus [43,44]. In models of Parkinson’s
disease [45] and Huntington’s chorea [46], dopaminergic
neurons were protected and motor deficits improved when
exposed to the GLP-1 analog exenatide.
Structural brain changes in schizophrenia and overweight
It is well-established that schizophrenia is characterized by
structural brain changes [47]. Already at first presentation
of symptoms, reductions in total brain volume and hippo-
campus volume, along with increased ventricle volume,
can be observed [48,49]. Moreover, the volumes of the
dopamine-sensitive striatal regions appear to be reduced
before initiation of antipsychotic treatment [50]. Progres-
sive cerebral volume loss, for example, enlarged ventricles,
is associated with more negative symptoms, cognitive
decline and a more severe course of illness [23]. Current
antipsychotic drugs have a limited effect on these symp-
tom dimensions, and interventions with convincing neuro-
trophic properties are still lacking in the treatment of
schizophrenia [51].
Growing evidence suggests that overweight is also asso-
ciated with structural brain changes and cognitive deficits
[24]. Large cross-sectional structural magnetic resonance
imaging studies of obese patients have shown both global
gray matter volume reductions (independently of age)
[52] and widespread regional structural abnormalities in
areas implicated in cognitive functions, impulse control
and reward processing (for example, prefrontal cortex
and striatum) [53,54]. These observations are supported
by magnetic resonance spectroscopy and single-photon
emission computed tomography studies suggesting that
elevated BMI is associated with both neuronal abnormal-
ities in frontal brain regions [55,56] and impaired cogni-
tive function [57]. In schizophrenia, reduced prefrontal
blood perfusion also appears to be associated with more
negative symptoms [58]. Besides similarities in gray mat-
ter changes in schizophrenia and obesity, also coinciding
white matter abnormalities in corpus callosum and
fronto-temporal tracts have been reported [59,60].
Although brain abnormalities associated with obesity
are already present in adolescents [61], it is still unclear if
structural brain abnormalities precede the disorder as is
the case in schizophrenia [62]. To our knowledge, weight
loss has not been associated with changes in brain
volume. In the available study addressing this issue, only
global brain volume was assessed [63], thereby rendering
the possibility that weight loss may still have a regional
effect on brain volume. Nevertheless, some of the cogni-
tive deficits associated with elevated BMI (that is, mem-
ory and attention/executive functioning) may be reversed
after intentional weight loss [64].
Functional brain changes in schizophrenia and
overweight
Functional neuroimaging studies have further established
the indications of a shared substrate for schizophrenia
and obesity. For example, satiety appears to be controlled
by the prefrontal cortex, which sends inhibitory inputs to
the limbic and paralimbic regions, thereby suppressing
hunger [65]. Studies using positron emission tomography
have compared obese, previously obese and lean subjects
and found abnormal cerebral blood flow in the insula
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and hippocampus in both obese and previously obese,
but not in lean subjects [65]. This suggests that in obe-
sity, disturbances in the satiety network are ‘trait’ rather
than ‘state’ dependent. Interestingly, abnormal hippo-
campal-prefrontal connectivity appears to be present in
first-episode schizophrenia, but also in subjects at high
risk for developing schizophrenia [66].
More recently it has also been suggested that the regio-
nal disturbances in the responsivity of the reward system
(for example, in the ventral striatum) may explain exces-
sive food intake, thereby increasing the risk of developing
overweight [67]. Of note, reward disturbances are also
becoming increasingly recognized in schizophrenia
patients as they even appear to precede the initiation of
antipsychotic treatment [68].
Potential clinical implications of GLP-1 analog treatment
First, encouraging and growing evidence supports that a
sizable and enduring weight loss can be obtained by GLP-
1 analog treatment in both diabetic and non-diabetic over-
weight or obese patients. Concurrently, an improved
glycemic control is obtained. Second, a striking overlap
appears to exist between key pathophysiological findings
in schizophrenia and overweight/obesity. The extent to
which this overlap is driven by the weight gain induced by
antipsychotic medication or is caused by interactions from
shared pathophysiological mechanisms warrants clarifica-
tion. A shared substrate between schizophrenia and over-
weight will likely involve shared genetic risk factors [13].
With changes in body weight, physiological mechanisms
may also come into play [64,69]. As such, exploration of
the cerebral effects of GLP-1 analogs in overweight/obese
subjects as well as in schizophrenia patients with antipsy-
chotic induced weight gain will help to elucidate this pro-
posed overlap between the two disorders.
An apparent way forward is initiation of clinical studies
addressing whether GLP-1 analog treatment can reduce
body weight in patients with antipsychotic-induced weight
gain. In fact, there is currently a study investigating
whether the GLP-1 analog exenatide can induce weight
loss in obese patients treated with olanzapine [70]. Since
previously un-medicated schizophrenia patients are in par-
ticularly high risk of developing metabolic side effects [71],
addressing whether or not GLP-1 analog treatment can
prevent weight gain is also pertinent. Finally, the indica-
tions of the procognitive and neurotrophic effects of GLP-
1 call for further investigation. If the progressive brain loss
and cognitive decline associated with schizophrenia and
overweight/obesity can indeed be ameliorated by GLP-1
treatment, this will have major implications for future
treatment of schizophrenia, but also for the treatment of
obesity. In psychiatry, particular priority should be given
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to the effects of early adjunctive GLP-1 treatment, that is,
in first-episode schizophrenia patients.
Current data certainly bear the connotation of adjunc-
tive treatment with GLP-1 analog as a potential ‘magic
bullet’ for addressing hitherto unresolved challenges in
schizophrenia. Table 1 summarizes the hypothetical impli-
cations of GLP-1 treatment in antipsychotic-induced
weight gain.
Conclusions
Psychiatry is facing a major unmet need for addressing the
severe metabolic side effects induced by antipsychotics.
While awaiting the development of antipsychotic drugs
with fewer side effects and more convincing neuroprotec-
tive and procognitive properties, an optimized treatment
of schizophrenia may be achievable through a rational
combination of drugs already registered, namely GLP-1
analogs. Current data converge towards adjunctive treat-
ment with GLP-1 analogs as a potentially new avenue in
the prevention and treatment of schizophrenia patients
with antipsychotic-induced weight gain. Clinical research
to support this idea is highly warranted.
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